Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.

Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients ...

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,509.46 today based on a price of $459.81 for VRTX at the time of writing.